BioMarin Pharmaceutical Financial Statements (BMRN)
|
|
|
|
Report date
|
|
|
25.02.2022 |
27.02.2023 |
26.02.2024 |
24.02.2025 |
26.02.2026 |
|
05.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1 846 |
2 096 |
2 419 |
2 854 |
3 221 |
|
3 242 |
|
Operating Income, bln rub |
|
|
-82.3 |
161.0 |
185.8 |
484.2 |
533.5 |
|
439.2 |
|
EBITDA, bln rub |
? |
|
47.4 |
265.4 |
306.8 |
650.5 |
572.9 |
|
482.5 |
|
Net profit, bln rub |
? |
|
-64.1 |
141.6 |
167.6 |
426.9 |
348.9 |
|
268.7 |
|
|
OCF, bln rub |
? |
|
304.5 |
175.9 |
159.3 |
572.8 |
828.0 |
|
874.3 |
|
CAPEX, bln rub |
? |
|
119.2 |
121.0 |
96.7 |
97.4 |
103.0 |
|
107.2 |
|
FCF, bln rub |
? |
|
185.3 |
54.9 |
62.6 |
475.4 |
725.0 |
|
767.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
1 458 |
1 432 |
1 701 |
1 789 |
1 951 |
|
2 023 |
|
Cost of production, bln rub |
|
|
470.5 |
503.0 |
532.1 |
580.2 |
736.8 |
|
780.3 |
|
R&D, bln rub |
|
|
628.8 |
649.6 |
746.8 |
747.2 |
921.9 |
|
942.0 |
|
Interest expenses, bln rub |
|
|
15.3 |
16.0 |
17.3 |
12.7 |
10.9 |
|
23.0 |
|
|
Assets, bln rub |
|
|
6 005 |
6 375 |
6 842 |
6 989 |
7 594 |
|
8 591 |
|
Net Assets, bln rub |
? |
|
4 266 |
4 603 |
4 952 |
5 658 |
6 087 |
|
6 212 |
|
Debt, bln rub |
|
|
1 090 |
1 093 |
1 096 |
649.5 |
642.9 |
|
1 440 |
|
Cash, bln rub |
|
|
1 014 |
1 292 |
1 074 |
1 138 |
1 561 |
|
2 222 |
|
Net debt, bln rub |
|
|
75.7 |
-198.1 |
21.9 |
-488.2 |
-917.7 |
|
-782.8 |
|
|
Ordinary share price, rub |
|
|
88.4 |
|
|
65.7 |
59.4 |
|
52.6 |
|
Number of ordinary shares, mln |
|
|
182.9 |
185.3 |
187.8 |
190.0 |
191.8 |
|
192.5 |
|
|
Market cap, bln rub |
|
|
16 155 |
0 |
0 |
12 490 |
11 398 |
|
10 121 |
|
EV, bln rub |
? |
|
16 231 |
-198 |
22 |
12 002 |
10 480 |
|
9 338 |
|
Book value, bln rub |
|
|
3 681 |
4 068 |
4 461 |
5 207 |
5 677 |
|
5 811 |
|
|
EPS, rub |
? |
|
-0.35 |
0.76 |
0.89 |
2.25 |
1.82 |
|
1.40 |
|
FCF/share, rub |
|
|
1.01 |
0.30 |
0.33 |
2.50 |
3.78 |
|
3.98 |
|
BV/share, rub |
|
|
20.1 |
22.0 |
23.7 |
27.4 |
29.6 |
|
30.2 |
|
|
EBITDA margin, % |
? |
|
2.57% |
12.7% |
12.7% |
22.8% |
17.8% |
|
14.9% |
|
Net margin, % |
? |
|
-3.47% |
6.75% |
6.93% |
15.0% |
10.8% |
|
8.29% |
|
FCF yield, % |
? |
|
1.15% |
|
|
3.81% |
6.36% |
|
7.58% |
|
ROE, % |
? |
|
-1.50% |
3.08% |
3.39% |
7.54% |
5.73% |
|
4.33% |
|
ROA, % |
? |
|
-1.07% |
2.22% |
2.45% |
6.11% |
4.59% |
|
3.13% |
|
|
P/E |
? |
|
-252.1 |
0.00 |
0.00 |
29.3 |
32.7 |
|
37.7 |
|
P/FCF |
|
|
87.2 |
0.00 |
0.00 |
26.3 |
15.7 |
|
13.2 |
|
P/S |
? |
|
8.75 |
0.00 |
0.00 |
4.38 |
3.54 |
|
3.12 |
|
P/BV |
? |
|
4.39 |
0.00 |
0.00 |
2.40 |
2.01 |
|
1.74 |
|
EV/EBITDA |
? |
|
342.2 |
-0.75 |
0.07 |
18.4 |
18.3 |
|
19.4 |
|
Debt/EBITDA |
|
|
1.60 |
-0.75 |
0.07 |
-0.75 |
-1.60 |
|
-1.62 |
|
|
R&D/CAPEX, % |
|
|
527.4% |
537.0% |
772.3% |
767.0% |
894.7% |
|
878.8% |
|
|
CAPEX/Revenue, % |
|
|
6.46% |
5.77% |
4.00% |
3.41% |
3.20% |
|
3.31% |
|
| BioMarin Pharmaceutical shareholders |
